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ABSTRACT
Background: The city of Bergen, Norway, is troubled by a large number of deaths caused by opioid related
overdoses. The number of deaths is also an indication of drug addict suffering, close family worries, drug
trade and other criminal activities, costs of policing and health care etc. While all of these are important
problems, focus in this thesis is on the number of deaths and on the effects of a policy called Supervised
Injectable Heroin (SIH) treatment.
Method: A system dynamics model is built in order to explain the high mortality rate among heroin users in
Bergen and to test the impact of SIH treatment. The model explains the flow of drug users from recruitment,
through imprisonment and opioid substitution treatment (OST), to quitting or death. In particular the model
is explicit about which periods the drug users are most susceptible to overdose deaths, when leaving prison
and when leaving OST. The data comes from existing literature and interviews with drug users. The model
behavior is analyzed with and without the policy impact, in order to understand how such a policy could
contribute to a lower death rate among opioid users. 
Results: The findings show that users recently released from prison and users who quit OST constitute the
majority of the victims of heroin related overdoses. When tested in the model, the SIH treatment showed
positive results towards reducing the fatal overdoses, especially among users quitting or being discharged
from OST. SIH treatment could contribute to a reduction in the overdose fatalities among the experienced
users of up to 37% per year with a clinic capacity of approximately 50-60 places.
Conclusions: The results shown by the model are a conservative estimation of the impact of SIH treatment.
In a small city like Bergen, with a stable number of injecting users where, many of them are also known by
the social services, good planning would be easier  and the impact of this policy could be even greater,
especially when combined with actions aiming to protect the users recently released from prison.
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“There is no such thing as moral phenomena, but only a moral interpretation of
phenomena”  
                                                   -Friedrich Nietzsche, Beyond Good and Evil
1 Introduction
This thesis is about Supervised Injectable Heroin treatment  (SIH), also known as Heroin Assisted Treatment,
specifically the way this treatment affects the number of fatal overdoses.   Despite many preventive and harm
reduction measures, opioid addicts suffer many physical and psychological problems which lead to a high
rate of premature mortality and morbidity. In Norway the average mortality rate among injecting users is
between 2% to 4% annually (Norwegian Annual Report (NR) to the European Monitoring Centre for Drugs
and  Drug  Addiction  EMCDDA, 2012),  which  is  between  1%  to  2% higher  than  most  of  the  western
countries. As a result, there has been an increasing concern about finding new effective ways to alleviate the
problem. In the following pages of this thesis the focus is on injecting heroin users,  since they are the once
most susceptible to fatal overdoses, though the data about the registered deaths might include a minority of
other opioid related deaths (see chapter 2.1 for the definition of drug related deaths by EMCDDA). 
Opioids  are  primarily  powerful  analgesic  drugs.  There  are  legal  opioids  such  as  Vicodin,  OxyContin,
Percocet and morphine and illegal ones such as heroin. Opioids give the users a strong feeling of euphoria
and can, in many cases, result in addiction. The majority of the studies presented in this paper are about
heroin addicts. Heroin addicts die from various causes, among which overdoses, suicides and accidents, with
overdose being the major cause of death (Darke et al., 2007). Darke and Hall (2003) have identified some
major  contributing factors  associated with the  risk of  overdose:  the  gender,  the  duration of  use  and its
inversely proportional relationship to the user's tolerance, the polydrug use, which means the use of multiple
drugs including alcohol, and the purity of the heroin (Darke et al., 2007a). There is also evidence of a direct
relationship  between  reduced  tolerance,  which  leads  to  increased  risk  of  overdose,  and  users  recently
released from prison,  as  well  as  users  who have recently been more  or  less  abstinent  (Darke and Hall
2003,Ingrid A. Binswanger et al., 2007,S R Seaman et al.,1998, Elizabeth L. C. Merrall et al.,2010, Farrell
and Marsden 2008, David Shewan et al.,2000). Under the light of these observations the hypotheses that will
be tested in this paper is whether the higher risk of fatal overdoses, under certain circumstances, which
include the duration of use and low tolerance periods after release from prison and after leaving OST, can
explain the high mortality rate of the users in the city of Bergen. Another question to be tested is whether the
SIH policy could have a positive effect on the high mortality rate among the heroin users in Bergen, and if
so, how such a goal would be reached.
In order to test this hypotheses a system dynamics model is built. The model includes the stocks the users go
through, from recruitment, through prison and OST, to quitting or death, as well as the high risk stocks the
users go through during their addiction period. The users are divided into new and experienced users not
only because the experienced users are most likely to experience a fatal overdose as mentioned above, but
also because they are the target group of the SIH policy tested in model. By using data from Bergen, the
model in an equilibrium situation, constitutes an explanatory model for the city. The robustness of the model
is tested and sensitivity analysis is conducted. 
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The SIH policy is applied in order to find out if such a policy would change the behavior of the model in
terms of a decreasing death rate. 
Having the death rates as exogenous variables, the model focuses on the time periods the users are most
susceptible to a fatal overdose. However, the model does not include several factors which, according to
literature, contribute to the specific number of overdoses for each stock. Such factors would be the gender of
the users, the purity of the heroin and the polydrug use. The most important reason for such variables not to
be included in the model is that there is still research to be done in order to determine to what extent these
factors affect the number of fatal overdoses. Furthermore, only the flows of experienced users are explicit in
the model, not those of the new users. This is done in order to avoid a ''black box'' model which fails to show
in a simple way the basic loops the users go through.
The Haukeland University Hospital of Bergen, recently proposed SIH as a way for the city to deal with the
high mortality rate among the heroin addicts. Due to a dramatic increase in heroin related deaths between the
1980s and the 1990s, the SIH policy was introduced in Switzerland. Research for the evaluation of this
policy has shown that it is an effective measure in order to reduce the number of fatal overdoses (Rehm et
al., 2005), especially among the old, once thought to be ''untreatable'', users. The goals of the SIH policy can
be summarized into four broad categories (Cattaneo et al., 1993):
(1) Reduce the number of new drug consumers/addicts.
(2) Increase the number of addicts who become abstinent.
(3)  Reduce  opiate-associated  health  consequences  and  the  social  discrimination  and  stigmatization  of
consumers and/or addicts.
(4) Protect society against drug-related harm and fight against drug-related organized crime.
The SIH policy is definitely not the solution to the heroin problem, and is not a substitute policy to the OST
treatment, rather than it has a different and more specific target group than the already existing policies. The
implementation of such a policy requires special facilities and trained clinical teams since direct medical
supervision is necessary.  In addition, political and moral impediments need to be surpassed in order for
policies to be effective and directed towards serving the general interest. 
The outline of the thesis will be as follows: First the theoretical basis for this paper will be introduced in
chapter 2. A closer examination of the problem through a review of the related literature and an overview of
the existing policies in Bergen, are included in this chapter. Chapter 3 describes the research methods used
for the purposes of this thesis; descriptions of the structure of the model and some of the variables used are
included in this chapter. Chapter 4 presents the findings as well as the results of the sensitivity analysis and
observations. Chapter 5 contains an analysis of the policy and discussion of the findings and other results of
the data collection. Chapter 6 contains the conclusion based on the data analysis and discussion.
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2 Mortality  among heroin users  and the  development  of  heroin  related
policies in Bergen
There is a variety of reasons which explain the high mortality among heroin users compared to non users.
This chapter approaches the problem through a review of the relevant literature. Some sociodemographic
characteristics are also apposed, aiming to a better understanding of the problem. There have been some
inconsistencies among definitions and data which are also explained.  The second part of the chapter presents
the development of the main heroin related policies in Bergen. 
2.1 The mortality problem through a review of literature
There is a significant amount of research dedicated to the heroin problem and the varying heroin addiction
treatment options. However, a common characteristic across the board is the shortage of data to a greater or
lesser extent. Computer-based treatment registrations did not exist in Norway, until as recent as 2010, when
the Norwegian National  Patient  Register  (NPR) started to  collect  data  through a  personally identifiable
register (NR 2011). The lack of discipline from the users' side when they are in treatment, further enhances
the difficulty of data collection. The shortage of data is also a result of the illegal nature of drugs. Thus big
part  of  the results  of  the research presented below and the one I  conducted,  should be interpreted with
caution.
There is a relatively small amount of data about Bergen compared to the amount of data about Norway as a
whole and Oslo in particular. The shortage of data about Bergen has been partly covered by data about the
whole country. The most essential source of data about Norway for this thesis was the Norwegian Annual
Reports to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Furthermore,  Føre
var and Utekontakten i Bergen reports provided me with some valuable data about Bergen. The 10 interviews
with  heroin  addicts  I  conducted,  although  limited  in  number  for  statistical  conclusions,   were  a  very
important source of insight into the heroin problem.
Despite the lack of data, the heroin problem is an old phenomenon and various aspects of it and its negative
outcomes have been studied.  We can separate  the  literature  about  heroin into three broad categories  of
research: a) research related to the supply side of the problem, b) research on the demand side of the problem
and c) research on treatment and treatment outcomes. In this paper the last two categories are of interest in
order to illustrate who the heroin addicts in Bergen are and why and how these people become victims of
their own habit. Due to the fact that the users of each country develop some trends which might differ from
user trends in other countries, the literature about Norway and Bergen in particular, is preferred over similar
research from other countries.
The EMCDDA defines problem use as “Injecting use of drugs or prolonged/regular use of opiates, cocaine 
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and/or amphetamines’. This means that everyone undergoing opioid substitution treatment (OST) who is
prescribed methadone or Subutex is  a problem user according to the EMCDDA’s definition”(NR 2013).
Moreover,  the  EMCDDA definition  of  drug  related  deaths  takes  into  consideration  people  who  are
recreational users or users of legal medicinal drugs that contain opioids and are exposed to the risk of a fatal
overdose. This is relevant to this thesis in the sense that the data taken from the Norwegian reports to the
EMCDDA, will include a minority of deaths not relevant to injecting heroin users  which this thesis deals
with. 
Bergen is the second largest city in Norway and belongs to the county of Hordaland. Estimations based on
the number of patients in OST and visits to nursing services, such as Strax huset, indicate that there are
around 1500 injecting users in the city. According to “Føre Var” reports, this number has been fairly stable
until 2007 and since then, it has slightly increased. However, this increase might not derive from an increase
in new users recruitment, but possibly  from the effect of the wide participation in OST programs which
extends the life expectancy of the users. There are no data about the number of people who only inject
heroin,  amphetamine  or  methamphetamine  in  Bergen,  but  calculations  about  Oslo  showed  that
approximately 30% to 35% of the total injecting users, primarily inject amphetamine (NR 2013). 
There is a general consistency among research from many countries, about the sociodemographic conditions
of the users. A recent ten-year prospective cohort study (Lauritzen, Ravndal and Larsson, 2012) among users
in treatment, conducted by the Norwegian Institute for Alcohol and Drug Research (SIRUS), shows low
educational background and limited working experience. According to the same study the addicts suffer
enduring mental disorders such as recurring anxiety, depression and cognitive difficulties. There is evidence
towards similar mental disorders in a variety of research (Farrell et al.,1996; SINTEF 2003 Helsetilstand hos
tunge rusmiddelmisbrukere & SINTEF 2003  Helsetjenester for tunge rusmiddelmisbrukere). In 2012 the
proportion of those unemployed was as high as 80% of the total number of users in treatment in Norway
(NR2013). In addition, the gender distribution among people in treatment has been approximately 30% for
women and 70% for men for several years, with men in treatment being on average older than women (NR
2005). 
The majority of the heroin users are polydrug users. (Bretteville-Jensen, 2005; Waal, 2007; Darke and Hall,
2003;  Francesco Leri  et  al.,  2003;  Darke and Ross 1997,  Douglass and Khavari,1978,  Darke and Ross,
1997).  The  2012  survey about  patients  in  OST showed  parallel  use  of  illegal  morphine,  cannabis  and
benzodiazepines. To the question whether they take other drugs along with heroin, some heroin addicts I
interviewed, mentioned amphetamine, alcohol and Lyrica. The “Føre var” report (2012) about drug trends in
Bergen also supports these findings. To my question why they mix the drugs most of them answered that
getting a stronger effect is their goal, whereas one person treated with Suboxone, which contains an opioid
antagonist, said that he used amphetamines because he would need to stop his treatment for three days in 
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order for heroin to have an effect. This might be revealing for the practices of other users who are also under
treatment with opioid antagonists such as naloxone, which is widely used in Norway.
There is empirical evidence that the annual mortality rate among illicit opiate users is between 1% to 2%
(Fischer et al.,2002; Hall et al., 1999; Waal,1997; Rehm, 1990-1993; Darke and Ross, 2002;  Gronbladh et
al.,1990;  Oppenheimer  et  al.,1994; EMCDDA report  2011).  In  Norway the corresponding percentage is
between 2% to 4% annually (NR 2012). Figure 1 shows the estimated mortality rates among all adults (15-64
years) due to drug-induced deaths. According to the EMCDDA report, opioids were present in between 80%
to 90% of all cases. The toxicology of the drug related deaths showed that substances often found in addition
to heroin are alcohol, benzodiazepines, other opioids and, in some countries cocaine, which is consistent with
the data from Norway. Figure 1 illustrates the high mortality rate in Norway, bringing the country in the
second place, after Estonia, among other European countries.
 
               Figure 1: Estimated mortality rates among all adults (15-64 years) due to drug-induced deaths 
              (EMCDDA 2011)
The number of deaths in Norway reached a peak in 2001. Since then there has been a decline, a trend which
is possibly attributable to the increasing number of patients entering OST (NR2013). Table 1 shows the
number of deaths from 1991 to 2010 from Kripos and Statistics Norway.
  Table 1: Drug-related deaths 1991–2011. Total number of deaths and deaths broken down by gender 
 (Kripos and Statistics Norway)
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In Table 1, there are obvious differences between the number of deaths registered by the two agencies. The
numbers from Statistics Norway are higher than the deaths registered by Kripos. These differences derive
from the fact that, since 1996, the Statistics Norway figures are based on the EMCDDA definition for drug
related  deaths  which  is  broader  than  the  definition  used  by Kripos.  The  EMCDDA definition  includes
suicides and the deaths of the elderly above the age of 65 which, if removed, these differences become very
small until 2009, although bigger after 2009 and until today. The numbers I will used are also based on data
from Statistics Norway.
Figures 2 and 3, illustrate the number of deaths in 2010 and 2011 broken down by substance. Heroin was
responsible for the majority of the drug related deaths in 2011. The difference among heroin and other drugs
is even more obvious in the past years. Another observation about the numbers shown in Figures 2 and 3 is
that the number of methadone related deaths is increasing. 
                Figure 2: Drug-related deaths in 2010 broken down by substance. (SIRUS and Statistics Norway) 
Two comments are of importance about this observation: first, there is no differentiation between  deaths
caused by methadone and deaths where methadone was present in the blood at the time of death and second,
the majority of methadone-related deaths occur among persons not enrolled in the OST program (NR 2012).
 
           
         Figure 3: Drug-related deaths in 2011 broken down by substance. (SIRUS and Statistics Norway
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Among the most common causes of death we find overdoses, suicides, accidents and somatic causes such as
liver  diseases,  due  to  Hepatitis  C infection and AIDS (EMCDDA 2011).  According to  Statistics  Norway
though, there were only 9 deaths of problem drug users between 2006 and 2008 which had AIDS as the
underlying cause of death (NR 2010). The incidence of HIV among injecting users in Norway has remained
relatively low for many years with only 10-15 new cases per year (NR 2013). In addition, a 25-year follow-up
study by Gjeruldsen et al., 2003, on drug addicts hospitalized for acute hepatitis, showed that drug addicts with
Hepatitis die as often as non drug addicts with the same infection and that the difference between the two
groups is attributable, almost exclusively, to overdose mortality and suicide by use of drugs. Deaths indirectly
related to the use of drugs are not registered neither by Statistics Norway nor by Kripos (NR 2010) and are not
included in this study.
Overdoses prevail over other causes of death among the heroin users (Darke and Hall, 2003; Toprak et al.,
2009; Risser and Schneider, 1994; Farrell et al., 1996; Wood et al., 2003; Davidson et al., 2003; Warner and
Smith et al., 2002; Preti et al., 2001). Literature about overdoses in Norway, also provides similar evidence.
Andersen et al.,1996, found that poisoning fatalities account for 63% of the mortalities whereas, Eskild et
al.,1993 concluded that 67% of the total number of drug related deaths are due to overdoses (NR 2005). In
addition, two studies conducted by SIRUS showed the corresponding percentages to be 70% according to the
former study and 82% according to the latter study. Other causes of death contributing to the high mortality
and revealed by these two SIRUS studies, are included in the violent death category and are suicide, murder
and accidents (NR 2006). 
In Bergen there is a high number of fatal overdoses and also a relatively high number of women victims.
After reaching a peak of 32 overdoses in 2000, the number of fatal overdoses has been stable since 2006. As
shown in Figure 4 there has been an increasing trend since then, with 23 people dying due to overdose in
2010 (Utekontakten i  Bergen, 2011). According to the same report,  Oslo and Bergen had a similar fatal
overdose rate in 2009 with between 8,7 to 8,8 fatal overdoses per 100000 inhabitants. The corresponding
figures for Bergen in 2010 were around 11,3 per 100000 inhabitants. This is twice as many fatal overdoses as
in Trondheim, the third largest city in Norway.
                 Figure 5: Number of fatal overdoses in Bergen divided by gender (Hordaland police)
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There is an apparent consensus throughout literature about the factors which lead to overdoses, fatal and non
fatal. The most important of them are the polydrug use, including alcohol (Darke and Hall, 2003; Kerr et al.,
2005; Backmund et al., 1999; Darke et al., 1996; Cook et al., 1998; Grass and Sticht, 2001; New York City
Department of Health and Mental Hygiene, 2011; Perret et al.,2000; Schmidt-Kittler and von Meyer, 2000;
Risser and Schneider, 1994; Darke and Hall, 1995), the gender with respect to fatal overdose, since men are
more susceptible to fatal overdoses than women (Darke and Hall, 2003; Darke and Zador, 1996; Steentoft et
al.,1995,  Simonsen et  al.,  2007),  the  route  of  administration (Darke  and Hall,  2003;  Kerr  et  al.,  2005;
Bretteville and Amundsen, 2010), the purity of heroin (Darke and Hall, 2003; Toprak et al., 2009;Darke et
al., 1998) and the users' tolerance (Darke and Hall, 2003;  Merrall et al., 2010; Farrell and Marsden, 2007;
Shewan et al., 2000). In many of the Norwegian reports to the  EMCDDA,  based on research within the
country,  there are references to the same reasons as the causes of fatal overdoses (Ødegård et al., 2007;
Ravndal and Amundsen, 2010; Clausen et al., 2009; Bretteville and Amundsen, 2010).
The majority of the heroin users go through certain stages during their addiction period and imprisonment is
one of those stages. The proportion of imprisoned users though, depends both on the social conditions of the
country and the users, and on the legislation of the country. However, I will include below some numbers
from other countries along with Norway as an indication of the extent of the criminality problem among the
users. 
Since the majority of the users are unemployed, as mentioned above, it is of no surprise that they turn to
criminal  activities,  often  repeatedly,  in  order  to  finance  their  habit.  In  NR  2007  it  is  mentioned  that,
according to the Statistics Norway, from 17168 people convicted for property crimes 56% were convicted
again within 5 years and 10% were reconvicted for a drug offence as the most serious crime.  The results of a
meta-analysis of 60 studies for the statistical association between drug misuse and crime (Bennett et al.,
2008) showed that the odds of offending (property crime, theft, prostitution, crime, arrest, conviction, prison
and shoplifting consist the list of crime measure of the studies the meta-analysis was based on) are between 3
and 3.5 times higher for heroin users than for non heroin users. By all means, it is not implied that every user
has a criminal background. For example, a study conducted in England showed that in a sample of 1075
treatment clients, only 10% of those sampled was responsible for three-quarters of the 27000  acquisitive
criminal offences committed during a three months period.
In Norway there is a remarkable increase in the drug related criminality (SSB,  Kriminalitet og rettsvesen,
2009). Ødegård (2008) in his study, which included all Norwegian prisons, found that a percentage as high as
70%  of  the  total  inmates  reported  using  drugs.  Of  them 25%  reported  injecting  use  of  heroin  which
corresponds to 80% of the total number of heroin users in prison. As an indication of offending behavior, the
majority of the users I interviewed, when I asked them if they are aware of other heroin users dealing drugs,
answered that it is a common practice among the users in Bergen, to resort to dealing as a means to make 
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some extra money to finance their habit. 
There are various studies on deaths caused by overdose among heroin addicts after  release from prison
(Binswanger et al., 2007; Seaman et al., 1998;Farrell and Marsden, 2007, Seymour et. al., 2000; Darke et. al.,
2000). According to Darke and Hall, the fact that the users in prison inject heroin less frequently than they
normally do, leads to a substantial reduction of their tolerance to the drug. The high risk period is considered
to be the first two weeks after release from prison. A meta-analysis of drug-related deaths soon after release
from prison showed a 3 to 8 times increased risk the first two weeks after prison compared to the 3-12 week
with ''notable heterogeneity between countries'' (Merrall et, al., 2010). In a study among former inmates in
Washington the risk of death in the first two weeks after prison was 12.7 times the risk of deaths of other
residents of the state (Binswanger et al., 2007).  
A similar  procedure to the one mentioned above,  seems to be the cause for the elevated mortality rate
reported right after OST. A study conducted by SIRUS for the evaluation of different kinds of treatment in
Norway, showed that during OST, there was a reduction in street heroin use, corresponding to 69%. There
are various studies (Gerra et al., 2004; Kakko et al., 2003; Yancovitz et al., 1991; Hartel et al., 1995), which
also provide supportive evidence of the reduction in heroin use during OST, something that can further lead
to the users' low tolerance. A national study conducted by Clausen et al.,2008 in Norway, showed that the
post-treatment mortality rate was higher than both the pre-treatment and the during-treatment mortality rates
(3.5 vs 2.4 and 1.4 respectively). Overdoses prevailed among the causes of death, both before and after OST.
It is interesting to note that, while the high mortality rate after OST and after prison seem to have the same
causal factor (low tolerance due to limited use of drugs), the fatal overdose rate after prison is reported to be
much higher than the one after OST. However, since there are no data about the after prison overdose rate in
Norway, this comparison is between the post treatment mortality rate in Norway and the mortality rates after
prison reported by research in other countries. One possible explanation for this difference might be that the
users in OST, being free, are more able to be in contact with heroin while in treatment than the imprisoned
users. Another possible explanation could be that, release from prison combined with a celebration mood,
could lead to a greater intake of heroin and other drugs.
In the past, only few system dynamics models have been built  in order to analyze drug related issues. L.
Keith  Gardiner  and Raymond C.   Shreckengost  (System Dynamics  Review,  1987)  have built  a  system
dynamics model for estimating heroin imports into the United States. JB Homer has built a model for the
estimation of the national cocaine prevalence in the United States (System Dynamics Review, 1993). As far
as I am aware of, there are no system dynamics models dedicated either to treatments or to mortality among
heroin users.
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2.2 Development of the heroin related policies in Bergen
Since the late 1960s' when drugs became a social problem in Norway, successive governments have always
been  against  the  legalization  and  decriminalization  of  all  drugs.  ''  The  Government  declared  that  the
ambitious goal of a drug-free society would be firmly upheld, as a necessary expression of attitude towards
drugs.  The Storting confirmed its  negative attitude towards legalization or  decriminalization,  while  also
stressing that greater emphasis must be given to prevention, and not least prevention carried out within the
framework of NGOs (Innst. S.nr.40 (1998-99).'' (NR 2001). 
Although prevention oriented, policy makers in Norway realized already many years ago the need for harm
reduction measures. In 1991 the first trial of substitution treatment was initiated, including only HIV positive
users (NR 2001). Until then, the treatment system was abstinence oriented and was characterized by ''an
unwillingness to regard addiction as an illness'' (NR 2010).  The appearance of HIV was a decisive factor
towards  harm  reduction  policies  (Wodak,  2009)  both  in  Norway  and  in  other  countries. Substitution
treatment with methadone officially started in 1998 and in 2001 buprenorphine (preferably with naloxone)
was added to the program and has been steadily gaining ground since then. In 2012 only 44% of the patients
in OST were treated with methadone while the rest 56% were under buprenorphine treatment (NR 2013).
There are two main reasons contributing to this development. The first  reason is that  overdose fatalities
happen more often among patients treated with methadone, than among those treated with buprenorphine.
Secondly, it is easier for the users to shift from buprenorphine to methadone, if necessary, than vice versa
(NR 2010). In Bergen there are seven OST clinics today with around 950 clients. 
According to the same EMCDDA report (NR 2010), buprenorphine (in combination with naloxone) being
the first choice in substitution treatment, is one of the deviations from the WHO guidelines about substitution
treatment. There are two more deviations from the WHO guidelines. The second essential deviation is that
substitution treatment in Norway is not the first choice of treatment, as it is in other countries, ''unless it is the
most appropriate and adequate treatment option based on a professional assessment''.  To conclude, there is
one more deviation with respect to the doses of methadone and buprenorphine. 
Since 2006, within the framework of a pilot project, the drug addicts arrested for drug offences can avoid
imprisonment on the condition of joining a rehabilitation program. In Bergen, 17 people served alternative
sentences in 2008. This policy appears to be successful, in the sense that it keeps some users out of prison by
offering rehabilitation options and it was only a small minority among these people who re-offended. The
time frame, however, for such an observation appears to be small.
One of the most promising developments of the present year, regarding fatal overdoses in Bergen, is the
decision to start up a trial of distribution of naloxone spray. Naloxone is an opioid antagonist which can 
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prevent fatal overdoses by reversing the effect of the opioid substance used by the addict. Such a policy,
specifically targeting fatal overdoses, could have a positive impact against the overdose fatalities. The other
recent development  concerning heroin addicts is the decision  to close down the biggest ''heroin park''  in
Bergen, but such policies aim to improve the situation in the neighborhood and do not usually have any
impact on the heroin problem itself.  According to the police, when the same closing of the park happened in
the 1980's ''drug users simply spread into the city and then returned as soon as the police stepped down their
activity'' (The Local, June 4, 2014) 
3 Research method
In order to test my hypothesis I used a system dynamics model. This approach has a number of attractive
features: To begin with, it provides the potential to show average trends of the various and undisciplined
behaviors of the users in order to gain a better understanding of the mechanisms which contribute to the high
number of deaths. In addition it allows us to test, through simulations, the possible effects of a policy in the
future. The first part of this chapter contains descriptions of the boundaries of the model and in the second
part, the structure of the model is described.
3.1 Setting the model boundaries
The focus of this model is on the trends of the behaviors of the users, from recruitment to death and the time
periods when the users are more susceptible to death in order for interventions against overdose deaths to be
more effective. Thus, among the most important boundaries of this model is the users' recruitment. In some
papers, the amount of new users is proportional to the availability of the drug (Gardiner and Shreckengost,
1987). Without violating common sense, it seems natural to assume that the users recruitment is also a result
of  the  combination  of  two  effects:  the  positive  effect  of  the  number  of  people  who  are  users,  since
recruitment usually occurs within friendly environments and the negative effect of the reputation of heroin
either by recognizing heroin users in the street or by being informed about the deadly outcomes of the drug
through the media and school, friends or family. It is important to mention here, that the majority of the users
I interviewed told me that it is a matter of principle to only sell the drugs to people who are already known to
be users thus, they would not be part of new recruitment, at least not by selling drugs.  The model described
below, does not deal with the this issue and, in an equilibrium situation, has the recruitment of the users as an
exogenous variable which is equal to the total outflows of model, attributable to death and quitting drugs.
Another  important  boundary is  that  the  fractions  of  overdose  and deaths  from other  causes,  which are
variables in the model that affect the mortality flows, are also exogenous. Because it is impossible to predict
the personal behaviors of the users, I assume here that the users' practices, through a certain consumption of
street heroin, in combination with polydrug use, their gender and the other causal factors of fatal overdoses
and fatalities in general mentioned above, lead to these specific mortality fractions. Unless there are policies, 
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aiming to eliminate the deaths, for instance OST treatment, the injection rooms in Oslo, or the distribution of
naloxone spray, recently introduced in Bergen, we can only expect that the death rate among the users will be
similar to previously reported death rates. 
The same applies to the fraction of users who leave OST treatment, which is exogenous in the model and is
based on data on the retention rate in OST, from the national Norwegian reports to EMCDDA. The focus of
the model is on the increased risk of overdose after leaving treatment and not on the factors which lead to
such a decision.  Furthermore,  the  fraction of  users who complete treatment  is  based on such data.  The
fraction of users arrested is also exogenous and again reveals the focus of the model on the users who are in
prison and more specific, the users who are released from prison and have an increased risk of overdose.
3.2 Overview of the model
In order to understand the mechanisms responsible for the deaths, the model is in dynamic equilibrium,
which means that despite the fact that the stocks remain unchanged, there are both inflows and outflows in
the model. The model is relatively small, with six stocks describing the different phases the users go through,
and one stock describing the SIH treatment policy.  In order to achieve a better description, the model has
been disaggregated below into four subsystems: recruitment, OST, prison and the SIH treatment which is the
policy structure.
3.2.1 Recruitment
In an equilibrium situation, the recruitment of the users is equal to the total outflows of the model. As shown
in Figure 6, the users are divided into new and experienced users. The model does not include an outflow for
new users quitting heroin or starting OST at this point, because the majority of the injecting users look for
help for their drug problem after a considerable time period spent ''on the street''.  In the NR 2013, it  is
mentioned that, only 2.5% of the total users in OST are in the age group 21-25. In addition, in NR 2005 it is
reported that the average age of the first injection has shifted from 15.8 years in the 1970s to 25.1 years,
whereas the average age of clients in OST, as reported in the status survey of 2012 (NR 2013), was around
42 years.  It  is  also assumed here that the majority of the users will  not quit  injecting use of heroin by
themselves, due to the addictive nature of the drug. 
Another reason for the subdivision of the users into New and Experienced, is that the causal factors of the
fatalities mentioned in chapter 2.1 affect more the experienced users. Thus, the only outflow from the New
Users stock, is the total death rate for New Users, which is responsible for around one third of the total
number of deaths (NR 2013). 
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                                           Figure 6: Stock and flow diagram for recruitment
The total death rate depends on the number of users in the New users stock multiplied by the fraction of
these users dying each year. After spending 10 years, on average as New Users, the heroin addicts move to
the Experienced Users stock. There are three outflows from the Experienced users stock as shown in Figure
6: one is the overdose rate, given by the number of Experienced Users in the stock multiplied by the fraction
of overdose deaths, the other is the deaths from other causes and the last one is the quitting drug use flow.
The fraction of overdose deaths in the model is set to 0.01 as it is assumed that 70% of the total deaths (0.03)
are overdoses.
 In NR 2006 it is mentioned that there are only few users over the age of 60. In the model, the average
addiction duration is 20 years after the users have entered the Experienced Users stock, thus, the users would
quit drug use in their mid 50s.  The quitting drug use flow is given by the following equation:
    quitting drug use = Experienced__users/avr_addiction_duration
The rest of the outflows from the Experienced Users stock are not shown in Figure 6 but are explicitly
illustrated in the following descriptions of the model structures.
As stated previously in chapter 2.1, there is a considerable number of methadone related deaths. Since, the
majority of these deaths do not happen within OST, there might be a leakage of methadone from OST,
though such data were not found. In the model there could be a causal relationship between the number of
users in OST and the leakage of methadone which has an effect on the mortality rate outside of treatment,
either it is the experienced or new users who die from methadone overdose. Since the data were insufficient
to justify such a causal relationship, I preferred not to include it in the model. These deaths in the model, are
included in the mortality rate of young users and in the overdose rate from the Experienced Users stock. 
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3.2.2 The OST structure
The reason for OST being chosen over other kinds of treatment, is that OST attracts a larger number of users
compared to other kinds of treatment available in Bergen. The stock and flow structure of the users starting
and leaving OST is shown in Figure 7. The users' flow into OST depends on the number of the experienced
users, the OST capacity, and the total number of people leaving OST willingly, by being discharged or by
dying.
The following flow equation allows users to start OST:
starting OST = MIN(Experienced__users,(OST__capacity-OST_patients)/0.1+total_OST__outflow)
where total OST outflow is an auxiliary variable including the sum of the three outflows from the OST stock
as illustrated in Figure 7 and 0.1 is the time period for the OST administration to deal with the new clients
issue. It is assumed here that all the experienced users are willing to become OST clients.
                                 
                             Figure 7: OST structure Stocks and Flows
This assumption is a result of the rapid expansion of OST capacity, the fact that OST always works at full
capacity and the existence of waiting lists for OST. Furthermore, in NR 2012 it is reported that 9 out of ten
users were in OST in the end of 2011. The gap in OST created in the model by the lack of New Users, is
further filled, for all practical purposes, by the assumption that all the experienced users are willing to start
treatment.
In the model the OST capacity is stable at 800 clients. The last official data from “Føre Var” (2012) state that
the capacity of OST was 591 in 2010 and 728 in 2011.The capacity of OST today has been recently reported
to be around 1000 clients (Torheim,Bergens Tidende, May 30, 2014). In the model there is a stable capacity
of 800 people, chosen as an average number during the simulation years.
Due to a lack of computer-based registrations which allow observations on the time spent in treatment by
each user, it is difficult to make assumptions about the duration of treatment. In NR 2004 the average 
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duration is reported to be 450 days for buprenorphine patients and 862,5 days for methadone patients. There
were no further references on this issue in the following reports to the EMCDDA and it was not mentioned
whether the users leave treatment as cured or not. This means that in the model some people may stay in the
OST stock for an unrealistically long period. However, it is more important for the purposes of this thesis to
follow the distribution of users between the different stocks and the users who go through the high risk
stocks every year. The quitting drug use outflow, from the Experienced Users stock is the only way for the
users to be cured in the model during the 15-year simulation period.   
The Norwegian data about the retention rate in OST showed very good results compared to the majority of
the countries. Data from the whole country show that the retention rate in OST is around 0.92% per year.
According to NR 2010, the retention rate is calculated through the annual surveys from OST, by measuring
the total number of clients in the end of the year, in relation to the number of clients in the beginning of the
year and the number of new admissions that particular year. In the model the fraction leaving OST is 0.08
according to the data, although the kind of measurement mentioned above does not include some patients
leaving treatment before and after the survey is conducted.
As shown in Figure 7, there are three death flows related to the OST structure. The overdoses while the users
are in treatment, the deaths from other causes in OST and the fatal overdose rate after OST. The two death
rates in OST, are subdivided because there is a considerably low overdose rate in OST, while most of the
users who die during treatment have somatic causes as the underlying cause of death. According to the NR
2012, the total death rate in OST is, 1.4, with only 27% of the total number of deaths caused by overdoses.
Due to the fact that the time unit in the model is years and in order to allow a realistic accumulation of users
in the After OST stock, the users stay in the After OST stock for around 2,5 months with an increased
mortality rate of 0.5 which applies for the whole year and creates, in equilibrium situation, a death rate of 6
people per year. If the retention rate is somewhat higher than 0.08 mentioned above, and the mortality rate
post treatment is between 3.5% (NR 2012) and 8.2% (Zanis and Woody,1998) then the death rate per year
produced by the model is quite realistic. In this stock the users have a lower than usually tolerance for heroin
which leads to a higher fraction of fatal overdoses. No data were found about the time needed to develop
such a low tolerance. However, given the fact that withdrawal symptoms from heroin can begin 6 to 12 hours
after the last dose, we can assume that it does not take a long time for the users' tolerance to decrease. This
structure describes the double impact of OST on the fatal overdose rate, which is positive on the one hand,
for the users who stay in treatment, negative, on the other hand, for those who decide to quit.
3.2.3 The prison structure
Although in Bergen and Oslo there is a chance (under certain circumstances) for dependent users to serve
their sentences within a treatment institution and based on Ødegård's report (2008), there is still a 
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considerable  number  of  injecting  users  in  the  prisons  of  the  country. The  structural  components  of  the
imprisonment part of the model, are illustrated in Figure 8. 
The process described by this structure is similar to the OST structure described above in chapter 3.2.2. A
fraction of users with either more serious or repeated offending behavior is  not punished by fines as is
common practice in Norway, but with imprisonment instead. The value of the average time spent in prison is
difficult to determine due to the fact that the judges in Norway seem to evaluate each case separately, using
their discretionary power. 
                                     
                                                   Figure 8: Prison stock and flow diagram
                                                           
The offences the majority of the users commit (Snertingdal, 2010), are ''punished pursuant to the Act relating
to  Medicinal  Products  (Act  No 132 of  4  December  1992)  Section 24,  which  provides  for  a  maximum
sentence of up to two years’ imprisonment'' (NR 2013). One of the users I interviewed had recently been
sentenced to serve 2,5 years in prison and this also indicative of prison related practices in Bergen. In the
model this value of the time spent in prison is set to one year, as an average between some months and 2
years spent in prison.
It  is assumed here that only the experienced users spend time in prison. Although this is  not  a realistic
assumption it serves the simplicity purposes of the model. In order to avoid 6 additional flows (in and out of
prison and through the Recently Released stock, for both the New Users and the OST patients), I decided to
have an increased arrest rate from the Experienced Users stock which would create in the model the same
number of imprisoned users as there would be if the Users in Prison were arrested from all the three stocks.
Thus, in the model, the fraction of the Experienced users being sentenced is set to 0.5, which results in 50
people per year serving sentences in prison. According to  Ødegård's study (2008), and given the prison
capacity in Bergen, this is a realistic number.
After having served their sentence, the users go through the Recently Released stock back to the street. A
higher mortality rate, due to low tolerance, is applied here, than in the After OST stock (see chapter 3.2.2). I
have set the mortality rate to 0.9 in the model which gives a total of 8 overdose deaths per year among the 
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recently released  users.  Based on  a  meta-analysis  (Merrall  et  al.,  2010)  the  risk of  drug related deaths
increases from 3 to 8 times the first weeks after release from prison. This result adjusted to the mortality rate
and the number of people released from prison gives us approximately 8 people per year.  The structure of
the model as illustrated above, shows that the more users are imprisoned, the more users will have to go
through the high risk Recently Released stock.
3.2.4 The SIH treatment structure
The SIH treatment  was proposed by the  Haukeland University Hospital  in  Bergen as  a  solution to  the
problem of the high mortality rate among the heroin users of the city. This policy is applied in the model as
shown in Figure 9. The SIH treatment is a policy with a limited target group of users. This group consists of
experienced users, who have failed with other kinds of treatment and are deemed to be untreatable. Such
users in the model would be the ones who leave OST treatment, but instead of going to the high risk After
OST stock, a fraction of them is transferred to the SIHT stock.
                                             Figure 9: The SIH treatment (SIHT) structrure
The starting SIHT flow in the model is a rate resulting by the following equation:
starting SIHT= MIN(total_users_leaving_OST*fraction_starting_SIHT,(SIHT_capacity-
SIHT_patients)/0.1+total_SIHT_outflows)
Thus, the recruitment of the users to the policy stock, depends on the users leaving OST, the fraction of them 
we choose to recruit, and the capacity of the clinic adjusted to people who quit or may die each year. 0.1 is 
the time needed to for new people to be recruited. According to the EMCDDA report (2012) on the insights 
about heroin assisted treatment (Strang et al.,2012), the capacity of such clinics vary from, on average 30-65 
clients in the 6 European countries and Canada, where such clinics exist. Some sensitivity analysis tests on 
the capacity of the clinic, are included below, in the policy analysis chapter.
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Moreover, the leaving treatment flow to the After OST stock is given by the equation:
leaving treatment = total_users_leaving_OST*(1-fraction_starting_SIHT)
In the model, the fraction starting SIHT is 0 until 2014 and in 2015 impact of the policy is tested.
There are three outflows from the policy stock: one death rate flow which, adjusted to the death causes
shown in the rest of the model is set to 0.005, one of SIHT clients going back to the street and one of SIHT
clients going to abstinence treatment. I considered the results from Switzerland to be more representative of
the impact of SIHT policy since, in contrast with results from other countries, the Swiss results cover a six
year period (1996-2000). The Swiss experience showed that the majority of deaths in SIHT happened due to
AIDS (Rehm et al.,2005). In Norway the prevalence of AIDS among injecting users is very low and since
other causes of death such as cancer are not included in the “deaths from other causes” the fraction of people
dying in SIHT, set to 0.005 is quite representative. The mortality rate from other countries, is equally low
(Strang et al.,2012) and fatal overdoses is a rare phenomenon in SIHT. In addition, 
The retention rate  in  SIHT was observed to  be on average 70% per  year  (EMCDDA, 2012).  Relevant
research has revealed a higher retention rate for clients in SIHT that for clients in OST. If that is the case,
then the retention rate among SIHT clients in Norway would be more than 92% which is the retention rate in
OST. In the model the fraction leaving SIHT is set to 0.08% of the total number of clients, which is the same
as in OST.
To conclude, in the SIH treatment structure, there is also one outflow to abstinence treatment. Only the Swiss
experience was long enough, to reveal such a behavior. It is, however a very interesting response of the users
to shift to abstinence treatment after their experience with SIHT. In the model this fraction is set to 10% per
year as an average of the results from the Swiss results (Rehm et al.,2005). The model does not include an
abstinence oriented treatment sector. If it would, there would also be an after treatment high risk stock, but
again these users could be further absorbed by SIHT in order to avoid this high risk stock. The sensitivity
analysis I conducted on the impact of the policy on the fatal overdoses, as shown below in chapter 5.1,
includes simulations with and without this outflow to abstinence oriented treatment. The structure, as shown
in Figure 9, clearly illustrates that the clients of SIH treatment will not have to go through the 2 high risk
stocks. With a high retention rate and a low overall death rate the SIHT clients are considerably less likely to
die, especially from fatal overdoses. 
4 Findings
The validation and verification part of the model is a very important part of the modeling process in order to
ensure that the model meets the specified requirements and the targets set in the beginning of the process. In
addition, sensitivity analysis is equally important as a means of revealing to which variables the model is
most sensitive thus, which variables considerably change its behavior. The first part of this chapter contains a
description of the validation process of the model as well as some of the most important results of the 
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sensitivity analysis and observations. In the second part, there is a description of the findings through
simulation graphs of the model behavior and some discussion about them.
4.1 Validation of the model 
Since the model is small and based on simple equations, the validation process was taking place during the
building  process  of  the  model.  In  addition,  the  model  corresponds  to  the  description  of  the  problem
mentioned above. The loops the users go through, are based on research results and despite the fact that the
model deals with the personal decisions of the users, it captures the dominant trends among them. Moreover,
the stock and flow structures serve the purpose of this model; to show which users are more susceptible to
death and provide a basis for interventions such as the SIH treatment.  The equations are dimensionally
consistent and all the parameters used have a real world meaning. 
I  have  also  conducted  some  extreme  conditions  tests  which  showed  that  the  model  is  robust  in  such
conditions. For example, when there are no users, all the stock and flows of the model are equal to 0. 
                     Figure 10: Model response to a pulse of 5000 new users in 2018, during the validation process
When I  introduced a pulse  of  the  unrealistic  number  of  5000 new users  in  2018 the model  reacted as
expected, with an increase in the stocks and flows as shown in figure 10. 
To conclude, a detailed documentation of each variable of the model is provided in the APPENDIX.
4.1.2 Model sensitivity to some parameters
It is very important to test the sensitivity of the model to some important parameters or some parameters with
questionable values. In order to achieve this goal I conducted some sensitivity analysis tests.
One parameter the model is sensitive to, is the retention rate in OST. Retention rate per year is the number of
users staying in treatment during that year and in the model this number is determined by the fraction leaving
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OST per year. The data about Norway give a notably higher retention rate than the one reported in the
literature. For example, according to Fischer et al, 2002,  ''Treatment study reviews suggest that 30–70% of
subjects leave methadone treatment within the first  12–24 months, and many resist  methadone treatment
altogether''.  Due to the fact that no data about the retention rate in Bergen's clinics were found, the initial
value of 0.08 is taken from the Norwegian reports to EMCDDA and is about the country as whole.
I run four simulations of the model with the fraction leaving treatment set from 0.08(initial parameter value)
to 0.35 which is a relatively low average of the retention rates reported from other countries. The values were
0.08 for the first simulation and 0.17, 0.26 and 0.35 for the following. There is a marked increase in the total
number of overdose fatalities after every simulation. The results are shown in Figure 11.
                         Figure 11: Change in the number of total  overdose deaths during sensitivity analysis
                          Fraction leaving treatment:   1- 0.08,  2- 0.17,  3- 0.26,  4- 0.35
The main reason for such an increase is the number of people in the After OST stock. Figure 12 illustrates
the differences between the four simulations.
                          
                           Figure 12:Accumulation of users in the After OST stock, sensitivity analysis
                            Fraction leaving treatment:   1- 0.08,  2- 0.17,  3- 0.26,  4- 0.35
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Another variable the model is, as expected, sensitive to, is the OST capacity. I set the value from 200 people
(first simulation) to 1000 people (last simulation) and the results of the total overdose rate are shown in
Figure 13.
                         Figure 13: Total number of overdose fatalities, sensitivity analysis.
                           OST capicity : 1- 200  2- 467   3- 733  4- 1000
As shown in Figure 13 and as it has been proven in practice, the contribution of OST in reducing the number
of deaths among the injecting heroin users is essential. Without the OST there would be an accumulation of
experienced users without any kind of treatment, since for many of them, the abstinence oriented treatment is
a difficult option and they have already failed with it, often more than once. 
Another variable which the model was sensitive to, as regards the overdose deaths, was the fraction of people
being sentenced. The results are illustrated in Figure 14.
                    Figure 14: Total number of overdose fatalities, sensitivity analysis
                        Fraction being sentenced  1-0.5    2-0.3    3-0.1
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4.2 Model behavior
The model was able to regenerate the historical data quite well. The total number of the injecting users in
Bergen, is estimated to be stable and around 1500 people. Of them, and according to the Føre Var report
(2012) around 130 people primarily inject amphetamine and/or methamphetamine. These people are not of
interest for this thesis because the treatments the model deals with, have nothing to offer to people addicted
to amphetamine and methamphetamine. The model gives a number of 1537 people which is higher than the
1370 heroin users estimated in Bergen, according to the information mentioned above. On the other hand, it
is  often the case that  the users inject  these drugs and heroin as well,  so they are absorbed by OST. In
addition, underestimations about the number of drug users is a usual phenomenon due to the illegal nature of
the drugs. Although, different social services are likely to be familiar with the experienced users, there is a
''hidden'' population of new users with small possibilities to be known by such services and clinics. The
results of the simulation and comparison with the historical data are seen in Figure 15. 
  
              Figure 15: Total number of injecting users, comparison of the model results with the historical data
The last few years the average number of drug related deaths in Bergen was 44 (Bergens Tidende). However,
based on the data from SIRUS and Statistics Norway about  the  percentage of  deaths,  broken down by
substance, as shown in chapter 2.1 (Figure 3), 80% of these deaths are attributable to opioids. That would
give us an average of 35 opioid related deaths per year. As shown in Figure 16, the model matches the data
by producing 33 opioid related deaths per year.
                Figure 16: Total number of deaths, comparison of the model results with the historical data
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Recent data about the number of fatal overdoses in Bergen due to opioids specifically,  were difficult  to
obtain. The data I used in the model, were an average of the overdose deaths between the years 2010 and
2012. In 2010 and 2011 there were 23, per year, fatal overdoses in Bergen and 15 during the first half of
2012 (Utekontakten i Bergen, Figure 5- ch.2.1, Bergensklinikkene). The simulation results in comparison to
the historical data are illustrated in Figure 17.
                Figure 17: Total number of overdose deaths, comparison of the model results with the historical data
The data shown in Figure 17 are not further elaborated in order to show only the opioid related overdoses
because no such data about Bergen were found. However, if we multiply the total of 35 opioid related deaths
by 0.7 which, according to the literature about Norway, is an approximation of the number of the overdose
deaths among the total number of drug related deaths, we would get 25 opioid related fatal overdoses. The
data about Bergen show a total of 23 drug related fatal overdoses. Thus either it is the case that, in Bergen,
some overdoses are considered suicides (according to literature it is difficult to differentiate between the two
causes  of  death,  see  also  Farrell  et  al.,1996)  or  the  vast  majority of  the  fatal  overdoses  in  Bergen are
attributable to opioids.
The model shows 19 deaths due to opioid overdose per year. However, there is no separate overdose outflow
from the New Users stock but a total mortality rate per year instead. If we apply the percentage of fatal
overdoses to the mortality rate of the New User, we will get 4 additional fatal overdoses per year which
would give us 23 fatal overdoses. The reason for not having a separate overdose rate among the new users is
that, the majority of these users, still feeling healthy and like they can control their problem (see also Hausser
et al.,1999), they do not ask for help, thus interventions at this point although important, would probably be
of little value.
Figure  18  shows  the  overdose  rates  from each  stock.  The  model  shows  that  the  majority  of  the  fatal
overdoses happens after leaving OST and after getting released from prison with 6 and 8 overdoses deaths
per year respectively. The results show that the two loops the users go through, one through prison and one 
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through OST, are responsible for around 74% of the total number of fatal overdoses among the experienced
users, 61% of the total number of fatal overdoses and 42% of the total number of drug related deaths.
 
                 
                               Figure 18: fatal overdose rates broken down by stock of users
4.2.1 Observations
The model, replicates quite well the historical data with around 167 additional users. The data from Bergen
give a mortality rate of around 2.6% per year, whereas the model produces a lower death rate than expected
of around 2.14% of the total number of injecting users per year. This deviation might derive from some
differences between the Norwegian data and the data based on research from other countries. In Norway
there  are  more  data  about  the  injecting  users  as  whole  whereas  the  majority of  the  studies  I  used  are
dedicated to heroin abuse. In addition, as described above, some of the data used in the model are not about
Bergen in particular, but about Norway as whole. Thus, a smaller retention rate in Bergen's OST could easily
result  in a higher mortality rate in the model as shown in the sensitivity analysis chapter (4.1.2) above.
Furthermore, the overdose rates I used for the two low tolerance stocks, Recently Released and After OST,
were low averages of the numbers mentioned in different  studies.  The uncertainty of the data based on
statistical information could further explain such deviations.
Another important observation about the model is that, if there are no experienced users outside of OST,
there will be no imprisoned users. What we know is that people enrolled in OST and new users, also serve
sentences in prison. However the treatment which, essentially reduced the criminal activity among the users,
is SIH, since pure heroin is provided to them and they do not need to resort to criminal activities in order to
buy it. This means that, unlike the other stocks in model, the majority of SIHT clients would not be part of
the imprisonment loop as shown in the model.
According to Torheim (Bergens Tidende, May 30, 2014), in 2012 there were 18 fatal overdoses in Hordaland
with methadone as the underlying cause of death. There are not any data yet, about whether these people
were enrolled in OST or not. The results from previous years suggest that in the majority of methadone- 
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related deaths, the users were not enrolled in OST (NR 2012). A study in New South Wales, Australia (Darke
et al., 2009) showed that methadone cases were significantly more likely to be diagnosed with pre-existing
systemic  pathology  such  as  cardiac,  pulmonary,  hepatic  and  renal  disease  and  multiple  organ  system
pathology. According to the same study there are good reasons to believe that systemic disease plays an an
important role in fatal opioid overdose cases.
The model  does  not  include separate  fractions  for methadone and heroin related overdoses.  Due to the
polydrug use and the different kinds of systemic diseases the users might suffer, it is difficult to predict or
categorize such deaths. However, this observation does not negate the fact that such deaths are more likely to
happen among experienced users going through the high risk stocks as shown in the model. It does underline,
though, the possibility of leakage of methadone from OST. Such phenomena can be prevented to a certain
degree by reducing as much as possible the take away doses and informing the users, even those not enrolled
in OST, about the dangers of methadone. The contribution of OST has long been proven and arguments
about the deaths caused by methadone cannot obscure the fact that the majority of the users benefit from
OST. 
At  this  point,  it  is  important  to  mention  that despite  the  fact  that  there  is  research  evidence about  the
relationship between the combination methadone- benzodiazepine and respiratory depression (Lintzeris et
al., 2006, 2007; Darke et al.,2009), it seems to be the case in Norway that around one third of the total
number of OST patients, are being prescribed benzodiazepines by a doctor (NR 2013). Although, it is not
mentioned in the report whether benzodiazepines are prescribed to methadone or buprenorphine patients, a
simultaneous leakage of methadone and benzodiazepines in the black market could contribute to such a high
number of methadone related overdoses.
To conclude, the model does not include the residential (abstinence oriented) treatment. In Norway there are
around 1900 in-patient places for people with alcohol and drug problems. The lack of data about the patients
in residential treatment for Norway and Bergen in particular, did not allow for inclusion in the model. It is a
fact though, that among the heroin users, those who choose abstinence oriented treatment are a minority. This
kind of treatment would be of interest for this paper since the retention rate in treatment is connected to a
higher fatal overdose rate after leaving treatment.
5 Policy analysis
The first part of this chapter contains the results of the simulations of the impact of the SIH treatment on the
fatal overdoses and the total number of deaths, as well as some sensitivity analysis results regarding this
policy.  In  the  second  part,  the  most  important  aspects  of  this  policy are  discussed,  as  experienced  by
countries  which  have  already implemented  SIHT or  have  run  trials  in  order  to  test  its  effects.  Further
discussion about the policy and some implementation issues are also included in the second part of this 
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chapter.
5.1 Testing the policy in the model
The model described above constitutes the bases for testing the SIH treatment's impact on the fatal overdoses
in Bergen. This policy works as follows: a certain fraction of experienced users who have failed with OST,
are being offered the chance to be part of a supervised, self- administration of heroin system at a clinic. The
number of people to be part of SIH treatment as well as additional acceptance criteria are at the discretion of
the administration, however, some sensitivity analysis tests were conducted in the model and the results are
discussed below.
Of the people leaving OST per year (0.08% of the number of people in OST) a certain fraction is transferred
into SIHT depending on the desirable capacity of the clinic. It  is common practice among the countries
where SIHT is implemented, to recruit users who have failed with OST at least twice. In the model however,
the only admission criteria applied is to be along term user and to have failed with OST once. The simulation
period for the policy is from 2015 to 2025. Figure 19 illustrates the impact of SIHT on overdose deaths
among long term users, with different clinic capacities from 30 to 60 clients.
 
                     Figure 19: Policy impact on overdose deaths, sensitivity analysis
                        SIHT capacity : 1-30  2-40  3-50  4-60
The model showed that SIHT policy could contribute to a decrease in the overdose deaths equivalent to,
between 26% and 37% per year, thus between 5 and 7 fewer overdose deaths per year, depending on the
clinic capacity. This would be a very conservative approximation since in the model, clients are recruited into
SIHT under the sole condition of being experienced users and quitting OST. In the model 30 additional
clients in SIHT result  in only 2 fewer overdose deaths.  In practice however,  people responsible for the
selection of users to start SIHT, can use more sophisticated criteria such as the duration of use and the other
risk factors for overdose fatalities, as were stated previously in chapter 2.1.
The results shown in Figure 19, require that a fraction of 10% of the total clients in SIHT would leave heroin
assisted treatment to start with abstinence oriented treatment. This behavior was observed in Switzerland, 
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where the SIHT exists long enough for these kind of observations. When I simulated the model, setting the
fraction to  abstinence oriented treatment  to  0 the  corresponding decrease in  the  overdose fatalities  was
between 21% and 26%. However, a better a selection of SIHT clients, as mentioned above, could still result
in a further decrease. 
In the model, the reduction in the number of deaths is mostly attributable to the OST loop, ''cut'' by the SIHT
policy. Regardless the SIHT capacity, the model shows that if people who leave OST are recruited in SIHT
there will be a considerable reduction in the number of overdose deaths from the After OST stock, as shown
in Figure 20. 
              Figure 20: Impact of SIHT policy on overdose deaths after leaving OST
There is also a small reduction in the fatal overdose rate after prison but, as mentioned above in chapter
4.2.1, the structure of the model, with users being imprisoned only from the Experienced Users stock, does
not allow this part of the model to be sensitive to the policy. In addition, two of the clinics in Europe are
inside prison (Strang et al.,2012) and such a policy, would lead to greater reductions in the fatal overdose
rates from the Recently Released stock of users.
5.2 The experience of SIHT from other countries
Ernest Drucker quoted the American baseball player Yogi Berra when referring to the history of medically
controlled prescription of injectable heroin: ''It’s déjà vu all  over again''.  According to  Strang et al.,2012
EMCDDA report, for a brief period in the early 1900s there where clinics in 12 states in the United Stated,
which  legally  provided  opiates  to  addicts.  The  Harrison  Narcotic  Act,  passed  in  1914,  restricted  the
capability for doctors to prescribe such drugs and by 1919 such practices were officially illegal. In 1926, the
Rolleston Report gave the guidance for prescription of morphine and heroin to addicts. These drugs could be
prescribed to people with serious withdrawal symptoms and to people for whom such drugs were necessary
in order for them to be functional and live a ''normal'' life. The gradual reduction method, when possible, was
recommended to the doctors. By the 1970s, the responsibility of prescribing heroin and morphine, was 
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transferred to drug clinics in order to avoid private doctors' malpractices. The limited prescription of heroin
 and morphine and to a limited number of patients has continued until today, but the British model did not
include supervision of the users, like the model developed in Switzerland.
In the mid 1990s, Professor Ambros Uchtenhagen and colleagues concluded that the British model could be
improved and implemented in Switzerland. This improvement refers to the strict supervision of a limited
number of treatment -resistant users, while injecting heroin into special clinics. After the positive results, in
terms of health and social well being of users from the Swiss trial became known, other countries also begun
trials on the Swiss model. Today Germany, the Netherlands, Denmark and the United Kingdom have granted
approval for SIHT, whereas Spain, Canada have not been able to implement SIHT despite the fact that the
results from their trials are deemed to be positive. In addition, Belgium has recently started a trial of SIHT
(Strang et al.,2012).
The positive effects of SIH treatment, as regards the high mortality rate among the opioid users, can be
separated into to broad categories, the direct and indirect effects. The most important direct effect of this
policy, is that the users most susceptible to fatal overdoses are being supervised while injecting. According to
Darke and Zador (1996) instant death after an overdose is a rare phenomenon and in the majority of the
cases, an interval greater than 2 hours between overdose and death, is reported. This is a time period long
enough for interventions by the specialized teams in a SIHT clinic. Among the trials of SIHT, fatal overdoses
were rare. Furthermore, another important effect was the reduction of “street” heroin use as reported by
Strang et al., 2010.  In addition, in SIHT, there are no fluctuations in the purity which, according both to
literature (Darke et al.,1999) and to the interviews I conducted, such fluctuations also play a role in the
overdoses, fatal and non fatal.
As shown in the model, the SIH treatment interferes into one of the most dangerous for fatal overdoses loops
the users go through. By absorbing long term users soon after they have quit OST, the users do not have to
go back to the “street” with low tolerance but they are being offered some kind of protection into SIHT
instead. To conclude with the direct effects, injecting into the clinic prevents needle sharing between these
users and the street users which can also help in the direction of limiting the spreading of Hepatitis and other
infections which are common among the users in Bergen. 
The most important indirect effect, regarding the fatal overdoses, is the remarkable reduction in the criminal
activities  noticed  during  the  trials.  The  proportion  of  users  reported  income  from  illegal  activities  in
Switzerland,  declined  from 69% to  10% (Strang  et  al.,2012  EMCDDA).  Thus,  the  majority  of  people
recruited in SIHT, will not have to go through the high risk Recently Released stock, as shown in the model. 
A SIHT clinic into a prison or a recruitment in SIHT of recently released users, could further contribute to a
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reduction in overdose fatalities.
Another important finding from the Swiss trial, is that some users became interested in abstinence oriented 
treatment. According to Rehm et al., 2001, during a 3 year period, 29% of SIHT clients in Switzerland left
SIHT for abstinence oriented treatment. This behavior is revealing of the treatment having a positive impact
on the mental and psychological situation in order to take such a decision despite the fact that heroin is being
''offered'' to them.
On the other hand, compared to OST, more serious adverse events (SAEs) seems to happen within SIH
treatment. The definition of SAE according to  Strang et al.,2012 is ''an unanticipated problem involving
‘risk’ to participants that ultimately results in harm to the participant (impacts on the participant’s morbidity
and mortality) (e.g. unanticipated ‘risk’ requiring hospitalization or prolongation of existing hospital stay) or
to others. Many of the SAEs reported were overdoses and required treatment with opioid antagonists. 
5.3 Discussion on the policy
Since SIHT is a relatively new treatment, the results of it can been seen either through trials or through the
longer Swiss experience. In most of the trials the SIHT clients were compared to OST clients. One common
characteristic among the practices during the trials is that there are no take away doses. This way leakage of
heroin from SIHT became impossible. However, the design of SIHT trials varies across the countries. In the
Swiss trials, for example, some clinics provided heroin along with methadone whereas in other trials the
users were encouraged to take methadone if the weren't able to attend SIHT  (Strang et al.,2012)
I  will  mention  here  some  common  characteristics  of  the  outcomes  of  different  trials  that  were  also
statistically significant (for a more detailed description of the findings, also see Strang et al.,2012). To begin
with, the mental and physical status of the users was improved along with the family relationships and social
reintegration.  Furthermore,  among the most  important  findings,  as  stated previously,  is  the  reduction in
criminal activity compared to OST clients. The fact that users with the most problematic behaviors enter this
treatment add value to the outcomes when compared to OST clients.
The SIHT treatment was found to be cost effective compared to OST. The cost per patient per year was
estimated to be EUR 12700- 14500 depending on the clinic capacity (Switzerland), EUR 19000 (Germany)
and EUR 20400 (Netherlands). The costs of SIHT were found to be much higher than the costs of OST. This
difference mostly derives from the staffing costs of the SIHT clinics, since at least two people have to be
there in order to supervise the users and the clinics must be open every day and for extended hours (Strang et
al.,2012). Despite the high cost, SIHT was found to be more cost effective than OST both in Germany and
the Netherlands, where such estimations were available. The advantage of SIHT in terms of costs, came from
reduced costs in criminal procedures and imprisonment.
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6 Conclusion
In this thesis, I have tried to combine up to date research findings about opiod related deaths, with focus on
fatal  overdoses,  with some trends among the behaviors  of  heroin users  into a  system dynamics  model.
Understanding the dynamics of such behaviors and the dynamics of fatal overdoses provide the opportunity
for a better assessment of the new, controversial heroin assisted treatment and a base for the selection criteria
of the users into this treatment, in order to make it more effective and prevent as many deaths as possible.   
My research has shown that in Bergen 74% of the fatal overdoses among the long term users are attributable
to  low tolerance  towards  opioids,  which  is  developed  while  the  users  are  in  OST and  in  prison.  The
corresponding proportion of  these deaths among the total  number  of  fatal  overdoses is  61%. Using the
system dynamics model, I tested the SIHT policy in order to find out its contribution towards a reduction in
the overdose fatalities during a 10-year simulation period. With the SIHT policy targeting only the long term
users who are also former OST clients, the model showed that this policy could lead to a reduction of 37% in
the number of deaths due to overdose among the long term users. This goal can be achieved into a special
clinic with capacity of around 50-60 clients, which is an average capacity compared to the existing SIHT
clinics in Europe and Canada. This is a conservative approximation of the reduction of fatal overdoses, since
in the model only limited number of selection criteria to start SIHT could be applied. In real life though,
people responsible for the recruitment of users in SIHT can use more information about the situation of each
user and the possible risks. Even greater reductions in the number of fatal overdoses can be achieved through
a simultaneous recruitment of users recently released from prison in SIHT, even for a short period of time.
Heroin  addiction  is  a  multifaceted  problem and  that  is  the  reason  for  preventive  measures  being  very
important. However, the extent of problem, with users facing the risk of death from multiple causes, makes
harm reduction measures essential for lives to be saved. Norway can be characterized as a conservative
country in regard to heroin policies. The high prevalence of injecting users in Norway calls for more harm
reduction  measures,  since  there  are  some  people  who  do  not  respond  to  the  already existing  policies.
Erroneous interpretations of the problem of addiction and moral impediments should not stand in the way of
implementing policies targeted towards saving human lives.
6.1 Further research
The process of the model building revealed the need for further research in order to define some of the
variables as well as the need for further categorization of some data. There is very little research concerning
the contribution of the purity fluctuations and the polydrug use in the opioid related deaths. Such variables
could be useful both in the direction of further explaining the causes of overdoses and to better evaluate the
outcomes of different kinds of treatment such as OST and SIHT.
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Research  on  heroin  addiction  and treatment  reveals  a  shortage  of  data  pertaining  to  how many people
manage to quit drugs and what happens to the heroin users after leaving treatment. In addition, it would be
useful to categorize data about the people who quit OST with criteria such as the duration of use and the
number of discharges or willing exits from OST,  so that treatment resistant users can be identified and
offered help in time. 
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 Appendix
1 Model overview
 2 Model equations
The following equations  are  in  iThink format.  The letters  before each equation indicate whether it  is  a
STOCK (S), a flow (F), a constant (C) or an auxiliary variable (A). The documentation of the values used is
in the third part of the Appendix.
S Initial_becoming_experienced(t) = Initial_becoming_experienced(t - dt)
INIT Initial_becoming_experienced = 
OST_patients*(fraction_deaths_from_other_causes+fraction_od__in_OST+fract_finishing_OST)
+After_OST*fraction_od_after_OST+Recently__Released*Fraction_od__after_prison+Experienced__users
*(fraction_od_experinced_users+fract_other_causes+1/avr_addiction_duration)
S Initial_recruitment(t) = Initial_recruitment(t - dt)
INIT Initial_recruitment = Initial_becoming_experienced+New_Users*fraction_deaths_young_users
                                                                                  
F Recruitment = Initial_recruitment
                                                                                    35
                                                                                 
S New_Users(t) = New_Users(t - dt) + (Recruitment - becoming_experienced - mortality_rate_young_users)
* dt
INIT New_Users = Initial_becoming_experienced*Years_as_young
F mortality_rate_young_users = New_Users*fraction_deaths_young_users
C fraction_deaths_young_users = 0.01
F  becoming_experienced = New_Users/Years_as_young
C Years_as_young = 10 
S Experienced__users(t) = Experienced__users(t - dt) + (becoming_experienced + adjusted_rate_to_street +
to_street_from_SIHT_rate + adjusted_rate_to_street_from_OST - starting_OST - od_rate_out_of__treatment
- other_causes - arrestment_rate - quitting_drug_use) * dt
INIT Experienced__users = 100
F od_rate_out_of__treatment = Experienced__users*fraction_od_experinced_users
C fraction_od_experinced_users = 0.02
F death_rate_from_other_causes = Experienced__users*fraction_street_deaths_from_other_causes
C fraction_street_deaths_from_other_causes = 0.01
F quitting_drug_use = Experienced__users/avr_addiction_duration
C avr_addiction_duration = 20
F arrestment_rate = Experienced__users*fraction__being_sentenced
                                                           
 C fraction__being_sentenced = 0.5
S Users_in__Prison(t) = Users_in__Prison(t - dt) + (arrestment_rate - release_rate) * dt
INIT Users_in__Prison = Experienced__users*fraction__being_sentenced*avr_time_in_prison
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 F release_rate = Users_in__Prison/avr_time_in_prison
C avr_time_in_prison = 1
S Recently__Released(t) = Recently__Released(t - dt) + (release_rate - adjusted_rate_to_street - 
od_after_prison) * dt
INIT Recently__Released = (Users_in__Prison/avr_time_in_prison)/(Fraction_od__after_prison 
+1/Time_as_recently_released)
F od_after_prison = Recently__Released*Fraction_od__after_prison
C Fraction_od__after_prison = 0.9
F adjusted_rate_to_street = Recently__Released/time_as_recently_released
C time_as_recently_released = 0.2
F starting_OST = MIN(Experienced__users,(OST__capacity-OST_patients)/0.1+total_OST__outflow)
C OST__capacity = 800
C total_OST__outflow = deaths_from_other_causes_OST + od_rate_in_OST + leaving_treatment + 
finishing_treatment
S OST_patients(t) = OST_patients(t - dt) + (starting_OST - leaving_treatment - od_rate_in_OST - 
deaths_from_other_causes_OST - starting_SIHT - finishing_treatment) * dt
INIT OST_patients = 800
F finishing_treatment = OST_patients*fract_finishing_OST
C fract_finishing_OST = 0.03
F od_rate_in_OST = OST_patients*fraction_od__in_OST
C fraction_od__in_OST = 0.004
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F deaths_from_other_causes_OST = OST_patients*fraction_deaths_from_other_causes
C fraction_deaths_from_other_causes = 0.01
A total_users_leaving_OST = OST_patients*fraction_leaving__OST_treatment
C fraction_leaving__OST_treatment = 0.08
F leaving_treatment = total_users_leaving_OST*(1-fraction_starting_SIHT)
S After_OST(t) = After_OST(t - dt) + (leaving_treatment - od_rate_after_OST - 
adjusted_rate_to_street_from_OST) * dt
INIT After_OST = (OST_patients*fraction_leaving__OST_treatment)/
(fraction_od_after_OST+1/Time_as_recently_out__of_OST )
F adjusted_rate_to_street_from_OST = After_OST/Time_as_recently_out__of_OST
C Time_as_recently_out__of_OST = 0.2
C fraction_starting_SIHT = IF TIME <2015 then 0 else 0.8
F starting_SIHT = MIN(total_users_leaving_OST*fraction_starting_SIHT,(SIHT_capacity-
SIHT_patients)/0.1+total_SIHT_outflows)
C SIHT capacity = 60
A Total SIHT outflows  = to_street_from_SIHT_rate+starting_abst_treatment+total_death_rate_in_SIHT
S SIHT(t) = SIHT(t - dt) + (starting_SIHT - to_street_from_SIHT_rate - total_death_rate_in_SIHT - 
quitting_heroin) * dt
INIT SIHT = 0
F total_death_rate_in_SIHT = SIHT*fraction_deaths_in_SIHT
C fraction_deaths_in_SIHT = 0.005
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F quitting_heroin = SIHT*fraction_to_abstinence_treatment
C fraction_to_abstinence_treatment = 0.1
F to_street_from_SIHT_rate = SIHT*fraction_leaving__SIHT
C fraction_leaving__SIHT = 0.08
A total_injecting_users = Experienced__users + OST_patients + SIHT + Recently__Released + 
Users_in__Prison + After_OST+New_Users
A TOTAL_DEATHS = total_OD_DEATHS + mortality_rate_young_users + 
death_rate_from__other_causes_street + deaths_from_other_causes_OST
A total_OD_DEATHS = od_rate_after_OST+od_after_prison+od_rate_in_OST+od_rate_out_of__treatment
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3 Documentation 
In this part of the appendix there is a list with the values of each variable, the sources of the values and 
explanation when the numbers were further elaborated. In the parenthesis after the values, there the units of 
each variable as used in the model.
fraction_deaths_young_users = 0.01   (1/year)                                NR 2013, p.50, Fig 7  
Years_as_young = 10  (years)                                                          NR 2005, p.35 - NR 2012 p.31
fraction_od_experinced_users = 0.02     (1/year)                        NR 2012, p.37- NR 2005p.44 – NR 2006 p.31
fraction_street_deaths_from_other_causes = 0.01 (1/year)        NR 2012, p.37- NR 2005p.44 – NR 2006 p.31
avr_addiction_duration = 20    (years)                                          NR 2006, p.78
fraction__being_sentenced = 0.5   (1/year)                           Ødegård, E(2008) - Plan for opplæring innan
                                                                                               kriminalomsorga i Hordaland 2007-2008,  
                                                                                             http://www.bergenfengsel.no/avdelingene.html
avr_time_in_prison = 1  (years)                                                   NR2013, p.62
Fraction_od__after_prison = 0.9  (1/year)                            In order to determine this value I multiplied the
                                                                                              total number of released users per 
                                                                                              year (50)  by the average of the increased   
                                                                                              mortality rate after prison (Merrall et al., 2010).
                                                                                              That would be 8 people per year. Then I adjusted  
                                                                                              the mortality rate, because the inflow in the stock
                                                                                              is per year and the outflow is per 2,5 months.
time_as_recently_released = 0.2  (years)                             I chose this value in order to allow some    
                                                                                              accumulation of users in the Recently Released
                                                                                              stock
OST__capacity = 800          (people)                                    Føre Var (2012). In the model there is a stable  
                                                                                              capacity of 800 people, chosen as an
                                                                                              average number during the simulation years.
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fract_finishing_OST = 0.03  (1/year)                                     NR 2001, p.69, http://www.heroin-
                                                                                               detox.com/detoxing-buprenorphine-subutex-
                                                                                               suboxone/19995-what-percentage-sube-bupe-
                                                                                               methadone-users-do-really-manage-quit.html
                                                                                               Stimmel et al., 1978
fraction_od__in_OST = 0.004 (1/year)                                  NR 2012, p.37
fraction_deaths_from_other_causes = 0.01  (1/year)              NR 2012, p.37
fraction_leaving__OST_treatment = 0.08  (Unitless)             NR 2013, p.42 
 
Time_as_recently_out__of_OST = 0.2   (years)                  I chose this value in order to allow some
                                                                                              accumulation of users in the After OST stock
fraction_deaths_in_SIHT = 0.005 (1/year)                           Rehm et al.,2005. The fraction of deaths is 0.01,  
                                                                                               but I subtructed the AIDS cases (which were the 
                                                                                               majority) and the cancer cases. These causes of 
                                                                                               deaths are not included in the EMCDDA  
                                                                                               definitions of drug related deaths used in this  
                                                                                               model
SIHT capacity = 60                                                               Strang et al., 2012 p                                                
fraction_to_abstinence_treatment = 0.1   (1/year)                Rehm et al.,2005
fraction_leaving__SIHT = 0.3  (1/year)                                Rehm et al.,2005, EMCDDA insights New      
                                                                                               heroin-assisted treatment
                                                                                               Recent evidence and current practices of            
                                                                                               supervised injectable heroin treatment in Europe 
                                                                                               and beyond
The unit for all the flows in the model is person/year and for the stocks is people.
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